Jpmorgan Chase & CO Allogene Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.51 Trillion
Q3 2025

A detailed history of Jpmorgan Chase & CO transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 908,725 shares of ALLO stock, worth $1.12 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

908,725

Previous 908,725 -0.0%

Holding current value

$1.12 Million

Previous $1.13 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 07, 2025	SELL	$1.03 - $1.66 $4.35 Million - $7.02 Million	-4,228,072 Reduced 82.31%	908,725 $1.13 Million
Q1 2025 May 12, 2025	BUY	$1.4 - $2.84 $1.96 Million - $3.98 Million	1,400,665 Added 37.49%	5,136,797 $7.5 Million
Q4 2024 Feb 12, 2025	SELL	$1.84 - $3.22 $646,528 - $1.13 Million	-351,374 Reduced 8.6%	3,736,132 $7.96 Million
Q3 2024 Dec 26, 2024	SELL	$2.08 - $3.5 $77,683 - $130,718	-37,348 Reduced 0.91%	4,087,506 $11.4 Million
Q3 2024 Nov 08, 2024	SELL	$2.08 - $3.5 $77,683 - $130,718	-37,348 Reduced 0.91%	4,087,506 $11.4 Million

Q2 2024 Dec 26, 2024	BUY	$2.23 - $4.38 $83,286 - $163,584	37,348 Added 0.91%	4,124,854 $9.61 Million
Q2 2024 Aug 12, 2024	SELL	$2.23 - $4.38 $2.36 Million - $4.63 Million	-1,057,125 Reduced 20.4%	4,124,854 $9.61 Million
Q1 2024 Dec 26, 2024	BUY	$2.92 - $5.63 $3.2 Million - $6.16 Million	1,094,473 Added 26.78%	5,181,979 $23.2 Million
Q1 2024 May 10, 2024	SELL	$2.92 - $5.63 $5.04 Million - $9.71 Million	-1,724,782 Reduced 24.97%	5,181,979 $23.2 Million
Q4 2023 Dec 26, 2024	BUY	$2.28 - $3.5 $6.43 Million - $9.87 Million	2,819,255 Added 68.97%	6,906,761 $22.2 Million
Q4 2023 Feb 12, 2024	SELL	$2.28 - $3.5 $9,395 - $14,423	-4,121 Reduced 0.06%	6,906,761 $22.2 Million
Q3 2023 Nov 14, 2023	BUY	$3.17 - $5.96 $2.46 Million - $4.63 Million	776,487 Added 12.66%	6,910,882 $21.9 Million
Q2 2023 Aug 11, 2023	BUY	$4.53 - $6.74 $5.03 Million - $7.48 Million	1,109,851 Added 22.09%	6,134,395 $30.5 Million
Q1 2023 May 18, 2023	BUY	$4.92 - $8.21 $519,286 - $866,532	105,546 Added 2.15%	5,024,544 $24.8 Million
Q1 2023 May 11, 2023	BUY	$4.92 - $8.21 $5.65 Million - $9.43 Million	1,148,715 Added 30.47%	4,918,998 $24.3 Million
Q4 2022 Feb 13, 2023	SELL	$5.62 - $11.11 $1.1 Million - $2.17 Million	-195,337 Reduced 4.93%	3,770,283 $23.7 Million
Q3 2022 Nov 14, 2022	SELL	$10.32 - $17.28 $5.55 Million - $9.29 Million	-537,374 Reduced 11.93%	3,965,620 $42.8 Million
Q2 2022 Aug 11, 2022	BUY	$6.78 - $12.28 $6.41 Million - $11.6 Million	945,877 Added 26.59%	4,502,994 $51.3 Million
Q1 2022 May 11, 2022	SELL	$7.65 - $15.29 $506,139 - $1.01 Million	-66,162 Reduced 1.83%	3,557,117 $32.4 Million
Q4 2021 Feb 10, 2022	BUY	$13.13 - $24.52 $3.96 Million - $7.39 Million	301,479 Added 9.08%	3,623,279 $54.1 Million
Q3 2021 Nov 12, 2021	BUY	$21.01 - $27.64 $69.8 Million - $91.8 Million	3,321,800 New	3,321,800 $85.4 Million

Others Institutions Holding ALLO

# of Institutions

182

Shares Held

138M

Call Options Held

76.6K

Put Options Held

36.2K

View Full List

About Allogene Therapeutics, Inc.

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $177M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

More about ALLO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Allogene Therapeutics, Inc. Transaction History